Structured benefit–risk assessment for enoxaparin, in the context of its label extension, for the extended treatment of deep vein thrombosis and pulmonary embolism, and prevention of its recurrence in patients with active cancer
Sign Up to like & getrecommendations! Published in 2024 at "Pharmacoepidemiology and Drug Safety"
DOI: 10.1002/pds.5795
Abstract: Guidelines recommend low‐molecular‐weight heparins (LMWHs) for patients with cancer‐associated thrombosis. However, until recently, only dalteparin and tinzaparin were approved in the European Economic Area (EEA) for these patients. This study compares the benefit–risk profile of… read more here.
Keywords: cancer; benefit risk; deep vein; treatment deep ... See more keywords
Prevalence, clinical reasons and associated factors of extended treatment duration for drug susceptible tuberculosis – a real-world experience
Sign Up to like & getrecommendations! Published in 2025 at "Scientific Reports"
DOI: 10.1038/s41598-025-97517-y
Abstract: Limited research has been conducted on the prevalence and factors associated with extended drug-susceptible tuberculosis (TB) treatment. A retrospective study enrolled drug-susceptible TB patients (January 2018 to December 2020) from a hospital’s registry to analyze… read more here.
Keywords: treatment; drug susceptible; factors extended; drug ... See more keywords
Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post‐hoc analysis of the Hokusai‐VTE Cancer study
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Thrombosis and Haemostasis"
DOI: 10.1111/jth.14561
Abstract: Patients with active cancer and venous thromboembolism (VTE) are at high risk of recurrence. Therefore, continued anticoagulant therapy beyond the initial 6 months is suggested in this patient population, but evidence supporting this approach is… read more here.
Keywords: vte; venous thromboembolism; cancer; extended treatment ... See more keywords
Low‐dose apixaban in extended treatment of cancer‐associated thrombosis: Less is more?
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Thrombosis and Haemostasis"
DOI: 10.1111/jth.15685
Abstract: We read with great interest the paper by Larsen et al. 1 about low-dose apixaban in extended treatment of cancer- associated thrombosis (CAT) after 6 months of full- dose treatment. The optimal duration of anticoagulant… read more here.
Keywords: dose apixaban; apixaban extended; extended treatment; treatment ... See more keywords
Predictors of slow clinical response and extended treatment in patients with extra-pulmonary tuberculosis in Pakistan, A hospital-based prospective study
Sign Up to like & getrecommendations! Published in 2021 at "PLoS ONE"
DOI: 10.1371/journal.pone.0259801
Abstract: The optimal duration of treatment in different forms of extrapulmonary tuberculosis (EPTB) is not clearly defined. This study aimed to identify predictors of slow clinical response and extended anti-TB treatment in EPTB patients. Socio-demographic, clinical,… read more here.
Keywords: treatment; slow clinical; predictors slow; response extended ... See more keywords